Gene therapy rules near

Chynoweth, Emma
March 2007
ICIS Chemical Business;3/5/2007, Vol. 2 Issue 56, p37
Trade Publication
The article reports on the call of the European biotechnology industry for the smooth adoption of the European Commission's Advanced Therapies Regulation. The industry is represented by EuropaBio. The new rules, which will be voted on by the European Parliament on March 13, focus on new medical techniques, including cell therapy, gene therapy and tissue engineering. The proposed regulation aims to provide a single evaluation system for advanced therapies across the European Union.


Related Articles

  • Raw materials intended to be used for gene, cell and tissue therapies: Legal and regulatory considerations. Bisson, Sophie // Journal of Commercial Biotechnology;Jan2014, Vol. 20 Issue 1, p54 

    This paper offers some insights on the European regulatory situation with respect to raw materials used in production of gene, cell and tissue therapy products, including advanced therapy medicinal products. By focusing on the existing EU and French rules, the purpose of this paper is to review...

  • A Brief Sunny Spell.  // European Pharmaceutical Executive;Jul/Aug2007, p21 

    The article focuses on the issues concerning the proposal of German diplomats to harmonize set of rules on advanced therapies. The European Union ministers has finally adopted the proposals on May 31, 2007, in which Europe will have a harmonized regulatory framework for cell therapy, gene...

  • Stem cell controversy to stall European tissue and cell therapy rules. Sheridan, Cormac // Nature Biotechnology;May2006, Vol. 24 Issue 5, p479 

    The article reports on the division among member states regarding issues on human embryonic stem cell research in the European Union. Supporters fear that the divided views could hamper the creation of a much awaited new regulatory framework to address the sale and marketing of cell therapies...

  • Progress in Gene and Cell Therapy for Cystic Fibrosis Lung Disease. Griesenbach, Uta; Alton, Eric W. F. W. // Current Pharmaceutical Design;2/11/2012, Vol. 18 Issue 5, p642 

    Although the development of gene therapy for cystic fibrosis (CF) was high priority for many groups in academia and industry in the first 10 to 15 years after cloning the gene, more recently active research into CF gene therapy is only being performed by a small number of committed, mainly...

  • Mesenchymal stem cell; biology, application and its role in regenerative medicine. Fard, A. Dehghani; Saki, N.; Ahmadvand, M.; Maymand, M. Mahmoodinia; Mohammadi, M. Mosahebi; Soleimani, M. // Scientific Journal of Iranian Blood Transfusion Organization;Jan2012, Vol. 8 Issue 4, p306 

    Background and Objectives Mesenchymal Stem Cells have extensive potential to proliferate and differentiate into different cell lineages. Their differentiation capability in vivo and in vitro makes them ideal tools for tissue engineering and regenerative medicine. Materials and Methods In the...

  • PRINCIPLISM VERSUS UTILITARIANISM IN TRANSLATIONAL MEDICINE ETHICS. Leabu, Mircea // Studia Universitatis Babes-Bolyai, Philosophia;2011, Vol. 56 Issue 2, p53 

    Translational medicine is a rather new research area, as it was mentioned for the first time in 1996, in the PubMed publication index, while bearing as a motto "From bench to bedside". Its complexity and novelty manage to raise a series of problems, in both medical and bioethical terms. The...

  • Multiple sources of non-embryonic multipotent stem cells: processed lipoaspirates and dermis as promising alternatives to bone-marrow-derived cell therapies. Freitas, Claudia; Dalmau, Sergio // Cell & Tissue Research;Aug2006, Vol. 325 Issue 3, p403 

    A body of evidence points to the existence of stem cell stores in adult tissues, in addition to the well-known hematopoietic stem cells from bone marrow. Many reports describe the ability of these multipotent cells (developmentally non-compromised with their organs of origin) to give rise to...

  • The Need for Increased Clarity and Transparency in the Regulatory Pathway for Gene Medicines in the European Union. Ylä-Herttuala, Seppo // Molecular Therapy;Mar2012, Vol. 20 Issue 3, p471 

    The author discusses the call for more clarity and transparency in the regulations for gene therapeutics in the European Union (EU). He cites a meeting in which issues and problems of biotechnology companies related to Advanced Therapy Medicinal Products (ATMP) were tackled. He suggests...

  • In This Issue.  // Molecular Therapy;Apr2011, Vol. 19 Issue 4, p632 

    An introduction to the journal is presented in which the editor discusses various topics including oncolytic virotherapy enhances antitumor vaccine therapy, cell-based gene therapy for the treatment of ischemic heart disease, and improving adoptive t-cell therapy by targeting IL-12 to the tumor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics